BOLD
Boundless Bio, Inc. NASDAQ Listed Jul 20, 2016$2.50
-0.20%
vs $2.51
Mkt Cap $56.3M
52w Low $0.96
84.4% of range
52w High $2.79
50d MA $1.54
200d MA $1.29
P/E (TTM)
—
EV/EBITDA
—
P/B
0.6x
Debt/Equity
0.5x
ROE
-59.0%
P/FCF
-1.2x
RSI (14)
84.20
ATR (14)
$0.10
Beta
-0.26
50d MA
$1.54
200d MA
$1.29
Avg Volume
2.4M
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.
9880 Campus Point Drive · San Diego, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 9, 2026 | AMC | -0.44 | -0.58 | -31.8% | 1.14 | +1.8% | +0.9% | +0.9% | -3.4% | -0.9% | +0.9% | — |
| Nov 5, 2025 | AMC | -0.53 | -0.62 | -17.0% | 1.26 | +3.2% | +0.0% | -2.4% | -1.6% | +4.1% | -2.4% | — |
| Aug 5, 2025 | AMC | -0.75 | -0.70 | +6.7% | 1.18 | -0.8% | +0.0% | -3.4% | -5.3% | +2.8% | +0.9% | — |
| May 9, 2025 | AMC | -0.68 | -0.71 | -4.4% | 1.44 | +4.2% | +3.5% | +4.0% | -3.9% | +13.4% | -2.4% | — |
| Mar 27, 2025 | AMC | -0.74 | -0.74 | +0.0% | 1.51 | -1.3% | -0.7% | +0.7% | -4.0% | +2.8% | -7.4% | — |
| Nov 7, 2024 | AMC | -0.76 | -0.74 | +2.6% | 3.32 | +2.4% | +5.4% | +2.3% | +3.4% | -3.5% | -9.2% | — |
| Aug 12, 2024 | AMC | -0.78 | -0.77 | +1.3% | 2.88 | +2.4% | +2.8% | +0.7% | +12.1% | -0.9% | +7.6% | — |
| May 13, 2024 | AMC | -0.55 | -12.27 | -2130.9% | 9.52 | -3.7% | -2.5% | +2.7% | +4.5% | -2.9% | +9.8% | — |
| Dec 31, 2023 | AMC | — | -0.55 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -0.59 | — | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | AMC | — | -0.56 | — | — | — | — | — | — | — | — | — |
| Mar 30, 2023 | AMC | — | -0.53 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.08 | $1.10 | +1.9% | +2.8% | +0.9% | +4.5% | +0.0% | -0.9% |
| May 28 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $1.30 | $1.34 | +3.1% | -7.7% | -2.5% | -6.0% | +2.7% | -0.9% |
| Dec 13 | Guggenheim | Downgrade | Buy → Neutral | — | $2.95 | $2.84 | -3.7% | -16.6% | +2.0% | +0.8% | -1.2% | +0.8% |
| Dec 8 | Evercore ISI | Downgrade | Outperform → In Line | — | — | — | — | — | — | — | — | — |
| Dec 5 | JP Morgan | Downgrade | Overweight → Neutral | — | — | — | — | — | — | — | — | — |
| Dec 4 | SVB Leerink | Downgrade | Outperform → Perform | — | — | — | — | — | — | — | — | — |
| Dec 3 | BMO Capital | Downgrade | Outperform → Perform | — | — | — | — | — | — | — | — | — |
| Dec 3 | SVB Leerink | Downgrade | Outperform → Market Perform | — | — | — | — | — | — | — | — | — |
| Dec 3 | Chardan Capital | Downgrade | Buy → Neutral | — | — | — | — | — | — | — | — | — |
| Dec 3 | Raymond James | Downgrade | Outperform → Perform | — | — | — | — | — | — | — | — | — |
| Dec 2 | Citigroup | Upgrade | Sell → Neutral | — | — | — | — | — | — | — | — | — |
| Dec 2 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | — | — | — | — | — | — | — | — |
| Dec 2 | Piper Sandler | Downgrade | Overweight → Neutral | — | — | — | — | — | — | — | — | — |
| Dec 2 | Guggenheim | Downgrade | Buy → Neutral | — | — | — | — | — | — | — | — | — |
| Dec 2 | Raymond James | Downgrade | Outperform → Market Perform | — | — | — | — | — | — | — | — | — |
| Dec 2 | BMO Capital | Downgrade | Outperform → Market Perform | — | — | — | — | — | — | — | — | — |
| Dec 2 | Wedbush | Downgrade | Outperform → Neutral | — | — | — | — | — | — | — | — | — |
| Dec 2 | Baird | Upgrade | Underperform → Neutral | — | — | — | — | — | — | — | — | — |
| Nov 18 | Evercore ISI | Upgrade | In Line → Outperform | — | — | — | — | — | — | — | — | — |
| Oct 3 | Baird | Maintains | Underperform → Underperform | — | — | — | — | — | — | — | — | — |
| Sep 2 | Chardan Capital | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Apr 16 | SVB Leerink | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Feb 24 | Chardan Capital | Upgrade | Neutral → Buy | — | — | — | — | — | — | — | — | — |
| Jan 10 | Guggenheim | Upgrade | Neutral → Buy | — | — | — | — | — | — | — | — | — |
| Dec 9 | Citigroup | Maintains | Neutral → Neutral | — | — | — | — | — | — | — | — | — |
| Nov 26 | JP Morgan | Maintains | Overweight → Overweight | — | — | — | — | — | — | — | — | — |
| Nov 7 | William Blair | Downgrade | Outperform → Perform | — | — | — | — | — | — | — | — | — |
| Nov 6 | William Blair | Downgrade | Outperform → Market Perform | — | — | — | — | — | — | — | — | — |
| Sep 7 | B. Riley FBR | Maintains | Sell → Sell | — | — | — | — | — | — | — | — | — |
| Aug 21 | Citigroup | Maintains | Neutral → Neutral | — | — | — | — | — | — | — | — | — |
| Aug 7 | Mizuho | Upgrade | Neutral → Buy | — | — | — | — | — | — | — | — | — |
| Jun 26 | Chardan Capital | Maintains | Neutral → Neutral | — | — | — | — | — | — | — | — | — |
| Feb 13 | Mizuho | Maintains | Neutral → Neutral | — | — | — | — | — | — | — | — | — |
| Dec 20 | H.C. Wainwright | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Dec 5 | BMO Capital | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Oct 17 | William Blair | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Oct 15 | Evercore ISI | Downgrade | Outperform → In Line | — | — | — | — | — | — | — | — | — |
| Oct 12 | Raymond James | Maintains | Market Perform → Perform | — | — | — | — | — | — | — | — | — |
| Sep 21 | BofA Securities | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Aug 17 | Evercore ISI | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Aug 15 | Piper Sandler | Maintains | Overweight → Overweight | — | — | — | — | — | — | — | — | — |
| Aug 15 | TD Cowen | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Aug 15 | Wedbush | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
No insider trades available.
8-K
Boundless Bio, Inc. -- 8-K Filing
Jun 23
8-K
Boundless Bio, Inc. -- 8-K Filing
Jun 17
8-K · 2.02
!! High
Boundless Bio, Inc. -- 8-K 2.02: Earnings Results
Boundless Bio (BOLD) reported earnings results, with detailed financial performance metrics available in the attached press release.
May 8
8-K · 1.02
!! High
Unknown — 8-K 1.02: Material Agreement Terminated
BOLD terminated a material agreement, which could reduce revenue, partnerships, or operational capabilities, warranting immediate investigation into the agreement's importance and replacement plans.
Apr 13
8-K · 5.02
!!! Very High
Boundless Bio, Inc. -- 8-K 5.02: Executive Change
Boundless Bio (BOLD) lost board member Christine Brennan effective March 3, 2026, potentially signaling internal governance shifts that investors should monitor for strategic implications.
Mar 9
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 2,695,455 | $3M | — | Mar 2026 |
| 2 | Citadel Advisors Llc | 1,342,131 | $1M | Reduced | Mar 2026 |
| 3 | Stonepine Capital Management, Llc | 597,682 | $657K | Reduced | Mar 2026 |
| 4 | Vanguard Capital Management Llc | 597,192 | $657K | New | Mar 2026 |
| 5 | Rbf Capital, Llc | 400,000 | $440K | — | Mar 2026 |
| 6 | Renaissance Technologies Llc | 399,000 | $439K | Added | Mar 2026 |
| 7 | Alyeska Investment Group, L.p. | 300,000 | $330K | — | Mar 2026 |
| 8 | Ensign Peak Advisors, Inc | 187,500 | $206K | — | Mar 2026 |
| 9 | Millennium Management | 99,875 | $110K | Reduced | Mar 2026 |
| 10 | Walleye Capital Llc | 79,248 | $87K | — | Mar 2026 |
| 11 | Morgan Stanley | 26,000 | $31K | Reduced | Dec 2025 |
| 12 | Citigroup Inc | 25,073 | $30K | New | Dec 2025 |
| 13 | Qube Research & Technologies Ltd | 17,492 | $19K | Reduced | Mar 2026 |
| 14 | Jane Street Group, Llc | 13,323 | $16K | New | Dec 2025 |
| 15 | Acadian Asset Management Llc | 12,610 | $12K | — | Mar 2026 |
| 16 | Pure Financial Advisors, Llc | 10,100 | $11K | New | Mar 2026 |
| 17 | Bnp Paribas Financial Markets | 178 | $196 | Added | Mar 2026 |
| 18 | Jpmorgan Chase & Co | 169 | $183 | — | Mar 2026 |
| 19 | Cwm, Llc | 8 | $9 | Reduced | Mar 2026 |
| 20 | Ubs Group Ag | 2 | $2 | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 8
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Growth Company Fund | 900,270 | $1M | Feb 2026 |
| 2 | Fidelity Series Growth Company Fund | 233,616 | $271K | Feb 2026 |
| 3 | Fidelity Growth Company K6 Fund | 229,453 | $266K | Feb 2026 |
| 4 | Fidelity Extended Market Index Fund | 67,712 | $79K | Feb 2026 |
| 5 | Ultra-Small Company Market Fund | 50,500 | $56K | Mar 2026 |
| 6 | iShares Micro-Cap ETF | 42,438 | $47K | Mar 2026 |
| 7 | Fidelity Series Total Market Index Fund | 10,969 | $13K | Feb 2026 |
| 8 | Fidelity Total Market Index Fund | 8,946 | $10K | Feb 2026 |
Valuation
Market Cap
$56.3M
Enterprise Value
-$51.5M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.01x
P/B
0.57x
P/S
—
P/FCF
-1.19x
EV/EBITDA
—
Shares Out
22.4M
Financials (TTM)
Revenue
$0
Net Income
-$56.0M
EBITDA
-$54.8M
Free Cash Flow
-$47.2M
Op Cash Flow
-$46.7M
EPS Basic
$-2.60
EPS Diluted
$-2.50
EPS Forward
$-2.38
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$157.1M
Total Liab.
$58.4M
Total Equity
$98.7M
Cash
$107.6M
LT Debt
$0
Book Value/Sh
$4.41
Debt/Equity
0.50x
Current Ratio
8.74
Quick Ratio
8.74
Returns & Growth
ROE
-59.0%
ROA
-37.0%
ROIC
-43.0%
Rev Growth YoY
+0.0%
EPS Growth YoY
+32.5%
Price Returns
2W
-6.5%
1M
-0.7%
3M
+25.0%
6M
+23.9%
12M
+31.8%
Technicals
52W High
$2.79
52W Low
$0.96
50d MA
$1.54
200d MA
$1.29
RSI (14)
84.20
ATR (14)
$0.10
Beta
-0.26
Avg Volume
2.4M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 24, 2026 10:28pm
· Source: financialmodelingprep.com